Oestrogen receptor β

What it means for patients with breast cancer

Valerie Speirs*, Pauline J. Carder, Sally Lane, David Dodwell, Mark R.J. Lansdown, Andrew M. Hanby

*Corresponding author for this work

Research output: Contribution to journalReview article

108 Citations (Scopus)

Abstract

Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.

Original languageEnglish
Pages (from-to)174-181
Number of pages8
JournalLancet Oncology
Volume5
Issue number3
DOIs
Publication statusPublished - 1 Mar 2004

Fingerprint

Estrogen Receptors
Breast Neoplasms
Tamoxifen
Biomarkers
History
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Speirs, V., Carder, P. J., Lane, S., Dodwell, D., Lansdown, M. R. J., & Hanby, A. M. (2004). Oestrogen receptor β: What it means for patients with breast cancer. Lancet Oncology, 5(3), 174-181. https://doi.org/10.1016/S1470-2045(04)01413-5

Oestrogen receptor β : What it means for patients with breast cancer. / Speirs, Valerie; Carder, Pauline J.; Lane, Sally; Dodwell, David; Lansdown, Mark R.J.; Hanby, Andrew M.

In: Lancet Oncology, Vol. 5, No. 3, 01.03.2004, p. 174-181.

Research output: Contribution to journalReview article

Speirs, V, Carder, PJ, Lane, S, Dodwell, D, Lansdown, MRJ & Hanby, AM 2004, 'Oestrogen receptor β: What it means for patients with breast cancer', Lancet Oncology, vol. 5, no. 3, pp. 174-181. https://doi.org/10.1016/S1470-2045(04)01413-5
Speirs, Valerie ; Carder, Pauline J. ; Lane, Sally ; Dodwell, David ; Lansdown, Mark R.J. ; Hanby, Andrew M. / Oestrogen receptor β : What it means for patients with breast cancer. In: Lancet Oncology. 2004 ; Vol. 5, No. 3. pp. 174-181.
@article{cd04ebf211164671a54cce0974aea40f,
title = "Oestrogen receptor β: What it means for patients with breast cancer",
abstract = "Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.",
author = "Valerie Speirs and Carder, {Pauline J.} and Sally Lane and David Dodwell and Lansdown, {Mark R.J.} and Hanby, {Andrew M.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1016/S1470-2045(04)01413-5",
language = "English",
volume = "5",
pages = "174--181",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "3",

}

TY - JOUR

T1 - Oestrogen receptor β

T2 - What it means for patients with breast cancer

AU - Speirs, Valerie

AU - Carder, Pauline J.

AU - Lane, Sally

AU - Dodwell, David

AU - Lansdown, Mark R.J.

AU - Hanby, Andrew M.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.

AB - Oestrogen receptor (ER) α is a well established prognostic marker in breast cancer, and all patients who are ERα positive receive tamoxifen as adjuvant endocrine therapy. Although ERα predicts a favourable disease outcome, the usefulness of ERβ as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ERβ has to patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=1342330354&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(04)01413-5

DO - 10.1016/S1470-2045(04)01413-5

M3 - Review article

VL - 5

SP - 174

EP - 181

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 3

ER -